RxDoctor Payments DataLook up a doctor →

Frank Saltiel, MD

Interventional Cardiology · Kalamazoo, MINPI 1215976543

Payments from drug & device makers

$60,060in general payments, 2019–2025

Across 561 payments — averaging $107.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$37K
  • Abbott$7K
  • Merit Medical Systems Inc$4K
  • Edwards Lifesciences$2K
  • Medtronic$1K
  • Boston Scientific$961
  • plus $8K from 38 others

What the payments were for

  • Royalty or licence$2,53513%
  • Travel & lodging$1,1226%
  • Food & beverage$14,47874%
  • Ownership interest$1,3947%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$60,060 in reported general payments places this provider in the 70th percentile of 187 interventional cardiology providers in Michigan.

See all interventional cardiology providers in Michigan

Medicare billing

Part B allowed, 2024
$114,101
Medicare patients
443
Services billed
999

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban217$249,049
EntrestoSacubitril/Valsartan77$83,039
XareltoRivaroxaban51$73,253
Repatha SureclickEvolocumab85$62,764
FarxigaDapagliflozin Propanediol17$18,193
Praluent PenAlirocumab15$16,884
JardianceEmpagliflozin13$14,133
Repatha SyringeEvolocumab12$12,165
Metoprolol Succinate446$10,346
Ranolazine ErRanolazine57$7,615
Atorvastatin Calcium396$6,523
ClopidogrelClopidogrel Bisulfate194$4,188
Isosorbide Mononitrate ErIsosorbide Mononitrate196$3,784
Diltiazem 24hr Er (Cd)Diltiazem Hcl60$3,606
Losartan Potassium201$3,232

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$641$83,03977 claims
Johnson & JohnsonXarelto$40$73,25351 claims
AstraZenecaFarxiga$246$18,19317 claims
Boehringer IngelheimJardiance$45$14,13313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 187 interventional cardiology providers in Michigan.

Other interventional cardiology in Kalamazoo

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →